Smith & Nephew (LON:SN – Get Rating) had its price objective reduced by research analysts at JPMorgan Chase & Co. from GBX 1,442 ($17.67) to GBX 1,243 ($15.23) in a note issued to investors on Thursday, MarketBeat.com reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 16.11% from the stock’s current price.
Other equities analysts have also issued research reports about the stock. Barclays cut their price objective on shares of Smith & Nephew from GBX 1,630 ($19.97) to GBX 1,550 ($18.99) and set an “overweight” rating on the stock in a research report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a GBX 1,700 ($20.83) price target on shares of Smith & Nephew in a research report on Thursday, July 21st. Credit Suisse Group dropped their price target on shares of Smith & Nephew from GBX 1,540 ($18.87) to GBX 1,400 ($17.15) and set an “outperform” rating on the stock in a research report on Thursday. Finally, Berenberg Bank dropped their price target on shares of Smith & Nephew from GBX 1,825 ($22.36) to GBX 1,490 ($18.26) and set a “buy” rating on the stock in a research report on Tuesday, July 26th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of GBX 1,476.60 ($18.09).
Smith & Nephew Price Performance
Shares of SN opened at GBX 1,070.50 ($13.12) on Thursday. The firm has a market cap of £9.34 billion and a PE ratio of 2,298.94. The firm’s 50 day moving average price is GBX 1,168.33 and its 200 day moving average price is GBX 1,221.05. The company has a debt-to-equity ratio of 53.62, a quick ratio of 0.84 and a current ratio of 1.78. Smith & Nephew has a twelve month low of GBX 1,002 ($12.28) and a twelve month high of GBX 1,440.89 ($17.66).
Insider Transactions at Smith & Nephew
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.